AU2017436815B2 - Anti-glyco-muc1 antibodies and their uses - Google Patents

Anti-glyco-muc1 antibodies and their uses Download PDF

Info

Publication number
AU2017436815B2
AU2017436815B2 AU2017436815A AU2017436815A AU2017436815B2 AU 2017436815 B2 AU2017436815 B2 AU 2017436815B2 AU 2017436815 A AU2017436815 A AU 2017436815A AU 2017436815 A AU2017436815 A AU 2017436815A AU 2017436815 B2 AU2017436815 B2 AU 2017436815B2
Authority
AU
Australia
Prior art keywords
antibody
seq
glyco
cells
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017436815A
Other languages
English (en)
Other versions
AU2017436815A1 (en
Inventor
Thayer White
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GO THERAPEUTICS Inc
Original Assignee
Go Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Go Therapeutics Inc filed Critical Go Therapeutics Inc
Publication of AU2017436815A1 publication Critical patent/AU2017436815A1/en
Application granted granted Critical
Publication of AU2017436815B2 publication Critical patent/AU2017436815B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3092—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4725—Mucins, e.g. human intestinal mucin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
AU2017436815A 2017-10-24 2017-10-24 Anti-glyco-muc1 antibodies and their uses Active AU2017436815B2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2017/058036 WO2019083506A1 (en) 2017-10-24 2017-10-24 ANTI-GLYCO-MUC1 ANTIBODIES AND USES THEREOF

Publications (2)

Publication Number Publication Date
AU2017436815A1 AU2017436815A1 (en) 2020-04-23
AU2017436815B2 true AU2017436815B2 (en) 2025-05-29

Family

ID=66247577

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017436815A Active AU2017436815B2 (en) 2017-10-24 2017-10-24 Anti-glyco-muc1 antibodies and their uses

Country Status (10)

Country Link
EP (1) EP3700936A4 (enExample)
JP (2) JP7358367B2 (enExample)
KR (2) KR102832078B1 (enExample)
CN (1) CN111479828B (enExample)
AU (1) AU2017436815B2 (enExample)
BR (1) BR112020008001A2 (enExample)
CA (1) CA3078812A1 (enExample)
IL (1) IL274202A (enExample)
MX (1) MX2020004220A (enExample)
WO (1) WO2019083506A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017436815B2 (en) * 2017-10-24 2025-05-29 Go Therapeutics, Inc. Anti-glyco-muc1 antibodies and their uses
US11970546B2 (en) * 2020-07-31 2024-04-30 R.P. Scherer Technologies, Llc Antibody specific for Mucin-1 and methods of use thereof
AU2022333837A1 (en) * 2021-08-27 2024-03-14 Peptron, Inc. Novel anti-muc1 antibody and use thereof
US20230250190A1 (en) * 2021-12-21 2023-08-10 Merus N.V. Binding domains against cancer-associated muc1
CN114796498A (zh) * 2022-01-27 2022-07-29 中国农业大学 抑制muc1糖基化修饰的物质在提高乳腺癌细胞对抗乳腺癌药物的敏感度中的应用
WO2024213106A1 (zh) * 2023-04-13 2024-10-17 江苏恒瑞医药股份有限公司 特异性结合egfr和muc1的抗原结合分子、其药物偶联物及其医药用途

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100034825A1 (en) * 2006-10-04 2010-02-11 Kobenhavns Universitet Generation of a cancer-specific immune response toward muc1 and cancer specific muc1 antibodies
US20150005474A1 (en) * 2003-01-23 2015-01-01 Glycotope Gmbh Recognition molecules for the treatment and detection of tumors
WO2015120180A1 (en) * 2014-02-05 2015-08-13 The University Of Chicago Chimeric antigen receptors recognizing cancer-specific tn glycopeptide variants
US20160145343A1 (en) * 2013-07-15 2016-05-26 Cell Signaling Technology, Inc, Anti-mucin 1 binding agents and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4976001A (en) * 2000-03-30 2001-10-15 Dyax Corp Mucin-1 specific binding members and methods of use thereof
EP2014302A1 (en) * 2007-07-12 2009-01-14 Institut Curie An antibody specific for the Tn antigen for the treatment of cancer
CA2707689A1 (en) * 2007-12-05 2009-06-11 Kyowa Hakko Kirin Co., Ltd. Monoclonal antibody capable of binding to heparin-binding epidermal growth factor-like growth factor
CN102264765B (zh) * 2008-10-28 2016-01-20 盐野义制药株式会社 抗muc1抗体
EP2281844A1 (en) * 2009-07-31 2011-02-09 Glycotope GmbH MUC 1 antibodies
AU2015254257B2 (en) * 2014-04-28 2021-02-25 Medicinal Chemistry Pharmaceuticals, Co., Ltd. Anti-MUC1 antibody or antigen-binding fragment of same, and use thereof
AU2017436815B2 (en) * 2017-10-24 2025-05-29 Go Therapeutics, Inc. Anti-glyco-muc1 antibodies and their uses

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150005474A1 (en) * 2003-01-23 2015-01-01 Glycotope Gmbh Recognition molecules for the treatment and detection of tumors
US20100034825A1 (en) * 2006-10-04 2010-02-11 Kobenhavns Universitet Generation of a cancer-specific immune response toward muc1 and cancer specific muc1 antibodies
US20160145343A1 (en) * 2013-07-15 2016-05-26 Cell Signaling Technology, Inc, Anti-mucin 1 binding agents and uses thereof
WO2015120180A1 (en) * 2014-02-05 2015-08-13 The University Of Chicago Chimeric antigen receptors recognizing cancer-specific tn glycopeptide variants

Also Published As

Publication number Publication date
JP2021510307A (ja) 2021-04-22
KR102832078B1 (ko) 2025-07-08
JP2024001073A (ja) 2024-01-09
AU2017436815A1 (en) 2020-04-23
CN111479828A (zh) 2020-07-31
CA3078812A1 (en) 2019-05-02
CN111479828B (zh) 2024-07-05
JP7358367B2 (ja) 2023-10-10
MX2020004220A (es) 2020-10-05
KR20200067885A (ko) 2020-06-12
EP3700936A1 (en) 2020-09-02
WO2019083506A1 (en) 2019-05-02
IL274202A (en) 2020-06-30
BR112020008001A2 (pt) 2020-10-20
KR102608763B1 (ko) 2023-11-30
EP3700936A4 (en) 2021-05-26
KR20230165874A (ko) 2023-12-05

Similar Documents

Publication Publication Date Title
US12065504B2 (en) Anti-glyco-MUC1 antibodies and their uses
US20230126689A1 (en) Anti-glyco-cd44 antibodies and their uses
AU2017436815B2 (en) Anti-glyco-muc1 antibodies and their uses
US20250304716A1 (en) Anti-glyco-muc1 antibodies and their uses
US20250136701A1 (en) Anti-glyco-cmet antibodies and their uses
US20250066498A1 (en) Anti-glyco-lamp1 antibodies and their uses
US20250101126A1 (en) Anti-glyco-muc4 antibodies and their uses
US20250326855A1 (en) Anti-glyco-cd44 antibodies and their uses
CN118354788A (zh) 抗糖-muc4抗体及其用途

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)